Cargando…

The presence of TIM‐3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status

Diffuse gliomas are aggressive brain tumors that respond poorly to immunotherapy including immune checkpoint inhibition. This resistance may arise from an immunocompromised microenvironment and deficient immune recognition of tumor cells because of low mutational burden. The most prominent genetic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sørensen, Mia D., Nielsen, Ole, Reifenberger, Guido, Kristensen, Bjarne W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412096/ https://www.ncbi.nlm.nih.gov/pubmed/33244787 http://dx.doi.org/10.1111/bpa.12921

Ejemplares similares

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
por: Li, Ming-Yang, et al.
Publicado: (2015)

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
por: Wang, Lei-Ming, et al.
Publicado: (2019)

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation
por: Ferreira, Monica Sofia Ventura, et al.
Publicado: (2020)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
por: Berger, Raffaela S., et al.
Publicado: (2019)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation
por: Sung, Chao-Hsien, et al.
Publicado: (2021)

Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
por: Dao Trong, P., et al.
Publicado: (2023)

Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine
por: Han, Yu, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas
por: Hosur, Bharat, et al.
Publicado: (2022)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms
por: QI, SONGTAO, et al.
Publicado: (2014)

Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients
por: Zhang, Zhe, et al.
Publicado: (2020)

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
por: Cordner, Ryan, et al.
Publicado: (2023)

CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
por: Marks, Asher, et al.
Publicado: (2021)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells
por: WANG, JU-BO, et al.
Publicado: (2014)

Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas
por: Wu, Shuang, et al.
Publicado: (2019)

Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
por: Pan, XiaoYong, et al.
Publicado: (2019)

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
por: Liu, Sidong, et al.
Publicado: (2020)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
por: Kim, Ja Eun, et al.
Publicado: (2015)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients
por: Qu, Chong‐Xiao, et al.
Publicado: (2020)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_27hh8fn9t1f0ftcov9lmsu6drb